432 related articles for article (PubMed ID: 21592861)
1. The case for a subunit vaccine against malaria.
Anders RF
Trends Parasitol; 2011 Aug; 27(8):330-4. PubMed ID: 21592861
[TBL] [Abstract][Full Text] [Related]
2. Pre-erythrocytic malaria vaccines to prevent Plasmodium falciparum malaria.
Ballou WR; Kester KE; Heppner DG
Chem Immunol; 2002; 80():253-61. PubMed ID: 12058643
[No Abstract] [Full Text] [Related]
3. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.
Miao J; Li X; Liu Z; Xue C; Bujard H; Cui L
Vaccine; 2006 Sep; 24(37-39):6187-98. PubMed ID: 16806600
[TBL] [Abstract][Full Text] [Related]
4. Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines.
Patarroyo ME; Patarroyo MA
Acc Chem Res; 2008 Mar; 41(3):377-86. PubMed ID: 18266328
[TBL] [Abstract][Full Text] [Related]
5. Malaria vaccine development using synthetic peptides as a technical platform.
Corradin G; Céspedes N; Verdini A; Kajava AV; Arévalo-Herrera M; Herrera S
Adv Immunol; 2012; 114():107-49. PubMed ID: 22449780
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
7. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
Stoute JA; Slaoui M; Heppner DG; Momin P; Kester KE; Desmons P; Wellde BT; Garçon N; Krzych U; Marchand M
N Engl J Med; 1997 Jan; 336(2):86-91. PubMed ID: 8988885
[TBL] [Abstract][Full Text] [Related]
8. The Plasmodium sporozoite survives RTS,S vaccination.
Snounou G; Grüner AC; Müller-Graf CD; Mazier D; Rénia L
Trends Parasitol; 2005 Oct; 21(10):456-61. PubMed ID: 16109504
[TBL] [Abstract][Full Text] [Related]
9. Genetically attenuated malaria parasites as vaccines.
Vaughan AM; Kappe SHI
Expert Rev Vaccines; 2017 Aug; 16(8):765-767. PubMed ID: 28612631
[No Abstract] [Full Text] [Related]
10. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.
Flueck C; Frank G; Smith T; Jafarshad A; Nebie I; Sirima SB; Olugbile S; Alonso P; Tanner M; Druilhe P; Felger I; Corradin G
Vaccine; 2009 May; 27(20):2653-61. PubMed ID: 19428875
[TBL] [Abstract][Full Text] [Related]
11. Vaccinating with the genome: a Sisyphean task?
Coppel RL
Trends Parasitol; 2009 May; 25(5):205-12. PubMed ID: 19359219
[TBL] [Abstract][Full Text] [Related]
12. Current Challenges in the Identification of Pre-Erythrocytic Malaria Vaccine Candidate Antigens.
Bettencourt P
Front Immunol; 2020; 11():190. PubMed ID: 32153565
[No Abstract] [Full Text] [Related]
13. Malaria vaccines: are we getting closer?
Epstein JE; Giersing B; Mullen G; Moorthy V; Richie TL
Curr Opin Mol Ther; 2007 Feb; 9(1):12-24. PubMed ID: 17330398
[TBL] [Abstract][Full Text] [Related]
14. Construction and evaluation of a multistage combination vaccine against malaria.
Zhang Q; Xue X; Qu L; Pan W
Vaccine; 2007 Mar; 25(11):2112-9. PubMed ID: 17241708
[TBL] [Abstract][Full Text] [Related]
15. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.
Lalvani A; Moris P; Voss G; Pathan AA; Kester KE; Brookes R; Lee E; Koutsoukos M; Plebanski M; Delchambre M; Flanagan KL; Carton C; Slaoui M; Van Hoecke C; Ballou WR; Hill AV; Cohen J
J Infect Dis; 1999 Nov; 180(5):1656-64. PubMed ID: 10515829
[TBL] [Abstract][Full Text] [Related]
16. The Plasmodium falciparum Cell-Traversal Protein for Ookinetes and Sporozoites as a Candidate for Preerythrocytic and Transmission-Blocking Vaccines.
Espinosa DA; Vega-Rodriguez J; Flores-Garcia Y; Noe AR; Muñoz C; Coleman R; Bruck T; Haney K; Stevens A; Retallack D; Allen J; Vedvick TS; Fox CB; Reed SG; Howard RF; Salman AM; Janse CJ; Khan SM; Zavala F; Gutierrez GM
Infect Immun; 2017 Feb; 85(2):. PubMed ID: 27895131
[TBL] [Abstract][Full Text] [Related]
17. Novel sporozoite-based ELISpot assay to assess frequency of parasite-specific B cells after vaccination with irradiated sporozoites.
Atre T; Robinson TM; Savransky T; Dutta S; Epstein JE; Bergmann-Leitner ES
Malar J; 2019 May; 18(1):186. PubMed ID: 31142328
[TBL] [Abstract][Full Text] [Related]
18. Designing malaria vaccines to circumvent antigen variability.
Ouattara A; Barry AE; Dutta S; Remarque EJ; Beeson JG; Plowe CV
Vaccine; 2015 Dec; 33(52):7506-12. PubMed ID: 26475447
[TBL] [Abstract][Full Text] [Related]
19. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
[TBL] [Abstract][Full Text] [Related]
20. [NANP]19-5.1. A malaria vaccine field trial in Nigerian children.
Reber-Liske R; Salako LA; Matile H; Sowunmi A; Stürchler D
Trop Geogr Med; 1995; 47(2):61-3. PubMed ID: 8592764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
